title: Propofol exerts anti-hepatocellular carcinoma by microvesicle-mediated transfer of miR-142-3p from macrophage to cancer cells.
abstract: OBJECTIVE
  We previously confirmed that propofol directly inhibited the viability, proliferation, and invasiveness of hepatocellular carcinoma cells in vitro. In this study, we investigated the mechanism underlying the anti-HCC effects of propofol.
  
  
  METHODS
  In vivo antitumor activity was investigated in tumor-bearing mice following an intraperitoneal injection of propofol, with or without clodrolip. The co-culture system was used to verify that miR-142-3p was transported from macrophages to HCC cells. A miR-142-3p inhibitor was used to down-regulate the expression of miR-142-3p.
  
  
  RESULTS
  Propofol drastically inhibited tumor growth in tomor-bearing mice through macrophage activation, and stimulated tumor-associated macrophages (TAMs) to secrete microvesicles (MVs), which delivered miR-142-3p to HCC cells, resulting in the inhibition of HCC cell invasion. In addition, MVs collected from the plasma of the tumor-bearing mice injected with propofol suppressed tumor growth. More importantly, down-regulation of the expression miR-142-3p reversed the effect of propofol on HCC cell migration.
  
  
  CONCLUSIONS
  This study reveals a novel role for propofol in the inhibition of HCC through MV-mediated transfer of miR-142-3p from macrophages to cancer cells in vivo.
authors.forename: Jian
authors.initials: J
authors.lastname: Zhang
authors.forename: Wei-feng
authors.initials: WF
authors.lastname: Shan
authors.forename: Te-te
authors.initials: TT
authors.lastname: Jin
authors.forename: Guo-qing
authors.initials: GQ
authors.lastname: Wu
authors.forename: Xiao-Xing
authors.initials: XX
authors.lastname: Xiong
authors.forename: Hai-yan
authors.initials: HY
authors.lastname: Jin
authors.affiliation: Department of Anesthesiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, 79 Qingchun Road, Hangzhou 310003, People's Republic of China. smzhu20088@163.com.
authors.forename: Sheng-mei
authors.initials: SM
authors.lastname: Zhu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001692:Biological Transport; D006528:Carcinoma, Hepatocellular / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D055252:Cell-Derived Microparticles / Q000187:drug effects / Q000378:metabolism*; D018920:Coculture Techniques; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008810:Mice, Inbred C57BL; D035683:MicroRNAs / Q000378:metabolism*; D015742:Propofol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D035683:MicroRNAs; C529102:Mirn142 microRNA, mouse; D015742:Propofol